Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- NewAmsterdam Pharma
- Study ID
- NCT05972278
- Phase
- PHASE1
- Status
- Active Not Recruiting
Conditions
- Lipid Metabolism
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- Obicetrapib — DRUG1 tablet daily
Study Details
To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
Key Dates
- Start date
- Dec 1, 2023
- Status verified
- Sep 2024
- Primary completion
- Sep 26, 2024
- Completion
- Oct 14, 2024
Study Design
- Enrollment
- 22 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Placebo Comparator: Obicetrapib placeboidentical matching placebo
- Experimental: Obicetrapib 10 mg10 mg tablets
Primary Outcome Measure
Treatment with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL). [ Time Frame: 8-12 week ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Archna Bajaj, MD | Philadelphia | Pennsylvania | 19104 | - |
Find similar trials in Philadelphia, PA
By research site